RxDoctor Payments Data

Jasmine Cutler, NP

Family · Colonial Heights, VANPI 1619598653

Payments from drug & device makers

$3,140in general payments, 2019–2025

Across 81 payments — averaging $38.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$590
  • Novartis$323
  • Boston Scientific$301
  • Esperion Therapeutics, Inc.$245
  • Actelion Pharmaceuticals US, Inc.$234
  • Amgen$233
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$3,04297%
  • Education$983%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,140 in reported general payments places this provider in the 85th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$38,409
Medicare patients
271
Services billed
562

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan114$130,683
EliquisApixaban94$85,019
XareltoRivaroxaban33$37,703
JardianceEmpagliflozin11$14,971
Ranolazine ErRanolazine94$8,813
BrilintaTicagrelor13$8,272
Prasugrel Hcl14$3,592
ClopidogrelClopidogrel Bisulfate86$1,164
Metoprolol Succinate106$1,085
Atorvastatin Calcium72$771
Isosorbide Mononitrate ErIsosorbide Mononitrate50$677
Amlodipine Besylate94$575
Carvedilol101$523
Valsartan17$514
Amiodarone Hcl24$484

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$323$130,683114 claims
PfizerEliquis$65$85,01994 claims
Johnson & JohnsonXarelto$230$37,70333 claims
Boehringer IngelheimJardiance$171$14,97111 claims
AstraZenecaBrilinta$51$8,27213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,332 family providers in Virginia.

Other family in Colonial Heights

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →